Antibodies directed against the conformational epitopes of the receptor-binding domain (RBD) of SARS-CoV-2 have been shown to be highly important for inhibiting virus infection by blocking the ACE2–RBD interaction and thus inhibiting virus entry [16,32,33,34]. The gene discussed is ACE2; the disease is viral infectious disease.